Allogeneic t-cell therapy for epstein-barr virus-positive posttransplant lymphoproliferative disease: Long-term follow-up

Transplantation

Volumn 90, Issue 1, 2010, Pages 93-94

  Haque, Tanzina ^a   McAulay, Karen A ^b   Kelly, Deirdre ^c   Crawford, Dorothy H ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN;

ALLOTRANSPLANTATION; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FOLLOW UP; HUMAN; LETTER; LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RELAPSE; REMISSION; SURVIVAL RATE; TREATMENT RESPONSE;

BLOOD DONORS; HERPESVIRUS 4, HUMAN; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TISSUE BANKS; TISSUE THERAPY;

EID: 77954590493     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d7c424     Document Type: Letter

References (4)

1. Heslop HE, Slobod KS, Pule MA, et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoprolif-erative disease in transplant recipients. Blood 2010; 115: 925.
2. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunother-apy of Epstein-Barr virus-associated diseases. J Immunother 2004; 27: 309.
3. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lym-phoproliferative disease using partially HLA-matched Epstein-Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399.
4. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lympho-proliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123.